Search
  1. Home
  2. Africa
  • News

WHO releases list of recommended AIDS drugs

    JOHANNESBURG

    In a move that could reduce the price of AIDS drugs for poor countries, the World Health Organisation (WHO) released its first list of safe HIV-related medicines on Wednesday.

    "We hope this project will help HIV positive people gain greater access to affordable HIV medicines of good quality," Dr Peter Piot, director of UNAIDS, said in a joint WHO and UNAIDS press release.

    The list released this week includes 11 antiretroviral drugs and five drugs for opportunistic infections. Of the total, 26 came from major manufacturers and 10 were from leading Indian generic drug producer, Cipla. The company was one of the first generic manufacturers to offer cheaper AIDS drugs to African governments.

    The decision means that there will be price competition among manufacturers of important antiretroviral treatments. Cipla products include nevirapine, zidovudine (AZT), and lamivudine (3TC), which make up a common AIDS cocktail.

    International humanitarian organisation, Medecines sans frontieres (MSF), welcomed the involvement of generic manufacturers but expressed concerns about the process used. "MSF regrets that the WHO prequalification process was started too late and that it has been so slow, considering that the first expressions of interest from producers were received in December 2000," the organisation said in a statement.

    "This is the beginning of an ongoing process," Daniela Bagozzi, communications officer for the health, technology and pharmaceuticals division of WHO, told PlusNews on Friday. WHO was still reviewing other products and suppliers and would add them to the list once they had met the set standards, she added.

    The absence of essential drugs such as fluconazole - used for treating thrush and cryptococal meningitis - was also a concern, as this would give users a false impression about their quality, the MSF statement added.

    "But we are really supportive of this project because we want the maximum number of patients to benefit from these drugs," Carmen Perez-Casas pharmaceutical coordinator for MSF, told PlusNews.

    To access the list:
    http://www.who.int/medicines/organization/qsm/activities/pilotproc/suppliers.doc

    This article was produced by IRIN News while it was part of the United Nations Office for the Coordination of Humanitarian Affairs. Please send queries on copyright or liability to the UN. For more information: https://shop.un.org/rights-permissions

    Share this article

    Our ability to deliver compelling, field-based reporting on humanitarian crises rests on a few key principles: deep expertise, an unwavering commitment to amplifying affected voices, and a belief in the power of independent journalism to drive real change.

    We need your help to sustain and expand our work. Your donation will support our unique approach to journalism, helping fund everything from field-based investigations to the innovative storytelling that ensures marginalised voices are heard.

    Please consider joining our membership programme. Together, we can continue to make a meaningful impact on how the world responds to crises.

    Become a member of The New Humanitarian

    Support our journalism and become more involved in our community. Help us deliver informative, accessible, independent journalism that you can trust and provides accountability to the millions of people affected by crises worldwide.

    Join